EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice

Samuel K Lee, Rida A Malik iD, Ji Zhou iD, Wei Wang iD, Peter L Gross iD, Jeffrey I Weitz iD, Rithwik Ramachandran iD, Bernardo L Trigatti iD

Arteriosclerosis, Thrombosis, and Vascular Biology · 2023

DOI: 10.1161/atvbaha.123.319767 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2023. Verfasst von Samuel K Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thrombosis and Atherosclerosis Research Institute (S.K.L., R.A.M., J.Z., W.W., P.L.G., J.I.W., B.L.T.), McMaster University, Hamilton, Ontario, Canad…. Hauptthemen laut MEDLINE: Atherosclerosis, Coronary Artery Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: SR-B1 (scavenger receptor class B type 1)/LDLR (low-density lipoprotein receptor) double knockout mice fed a high-fat, high-cholesterol diet containing cholate exhibit coronary artery disease characterized by occlusive coronary artery atherosclerosis, platelet accumulation in coronary arteries, and myocardial fibrosis. Platelets are involved in atherosclerosis development, and PAR (protease-activated receptor) 4 has a prominent role in platelet function in mice. However, the role of PAR4 on coronary artery disease in mice has not been tested. METHODS: We tested the effects of a PAR4 inhibitory pepducin (RAG8) on diet-induced aortic sinus and coronary artery atherosclerosis, platelet accumulation in atherosclerotic coronary arteries, and myocardial fibrosis in SR-B1/LDLR double knockout mice. SR-B1/LDLR double knockout mice were fed a high-fat, high-cholesterol diet containing cholate and injected daily with 20 mg/kg of either the RAG8 pepducin or a control reverse-sequence pepducin (SRQ8) for 20 days. RESULTS: Platelets from the RAG8-treated mice exhibited reduced thrombin and PAR4 agonist peptide–mediated activation compared with those from control SRQ8-treated mice when tested ex vivo. Although aortic sinus atherosclerosis levels did not differ, RAG8-treated mice exhibited reduced coronary artery atherosclerosis, reduced platelet accumulation in atherosclerotic coronary arteries, and reduced myocardial fibrosis. These protective effects were not accompanied by changes in circulating lipids, inflammatory cytokines, or immune cells. However, RAG8-treated mice exhibited reduced VCAM-1 (vascular cell adhesion molecule 1) protein levels in nonatherosclerotic coronary artery cross sections and reduced leukocyte accumulation in atherosclerotic coronary artery cross sections compared with those from SRQ8-treated mice. CONCLUSIONS: The PAR4 inhibitory RAG8 pepducin reduced coronary artery atherosclerosis and myocardial fibrosis in SR-B1/LDLR double knockout mice fed a high-fat, high-cholesterol diet containing cholate. Furthermore, RAG8 reduced VCAM-1 in nonatherosclerotic coronary arteries and reduced leukocyte and platelet accumulation in atherosclerotic coronary arteries. These findings identify PAR4 as an attractive target in reducing coronary artery disease development, and the use of RAG8 may potentially be beneficial in cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisCoronary Artery DiseaseAnimalsMiceCholatesCholesterolFibrosisMice, Inbred C57BLMice, KnockoutReceptors, LDLVascular Cell Adhesion Molecule-1Receptors, Proteinase-Activated

Stichwörter der Autor:innen

atherosclerosisblood plateletscoronary artery diseaselipidsmicereceptors, proteinase-activated

Substanzen

CholatesCholesterolReceptors, LDLVascular Cell Adhesion Molecule-1protease-activated receptor 4, mouseReceptors, Proteinase-Activated

Autor:innen und Institutionen

  • Thrombosis and Atherosclerosis Research Institute (S.K.L., R.A.M., J.Z., W.W., P.L.G., J.I.W., B.L.T.), McMaster University, Hamilton, Ontario, Canada.
  • Hamilton Health Sciences, Ontario, Canada (S.K.L., R.A.M., J.Z., W.W., P.L.G., J.I.W., B.L.T.).
  • Department of Biochemistry and Biomedical Sciences McMaster University, Hamilton, Ontario, Canada (S.K.L., W.W., J.I.W., B.L.T.).
  • Department of Medicine (R.A.M., J.Z., P.L.G., J.I.W.), McMaster University, Hamilton, Ontario, Canada.
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada (R.R.).

ORCID-Profile: Rida A Malik, Ji Zhou, Wei Wang, Peter L Gross, Jeffrey I Weitz, Rithwik Ramachandran, Bernardo L Trigatti

Förderung

  • CIHR

Zitieren

APA

Lee, S. K., Malik, R. A., Zhou, J., Wang, W., Gross, P. L., Weitz, J. I., Ramachandran, R., & Trigatti, B. L. (2023). PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.123.319767

Vancouver

Lee SK, Malik RA, Zhou J, Wang W, Gross PL, Weitz JI, et al. PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023. doi:10.1161/atvbaha.123.319767

BibTeX
@article{Lee2023,
  author = {Lee, Samuel K and Malik, Rida A and Zhou, Ji and Wang, Wei and Gross, Peter L and Weitz, Jeffrey I and Ramachandran, Rithwik and Trigatti, Bernardo L},
  title = {PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice},
  journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
  year = {2023},
  doi = {10.1161/atvbaha.123.319767}
}
Kostenlos starten →